HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV

Journal of Virology

Volumn 91, Issue 18, 2017, Pages

  Madhavi, Vijaya ^a   Wines, Bruce D ^a,b,c   Amin, Janaki ^d   Emery, Sean ^d   Lopez, Ester ^a   Kelleher, Anthony ^d,f   Center, Rob J ^a,b   Mark Hogarth, P ^b   Chung, Amy W ^a   Kent, Stephen J ^a,e   Stratov, Ivan ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BURNET INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f Lowy Packer Building   (Australia)

Author keywords

ADCC; Elite controller; Fc R; Vpu

Indexed keywords

EPITOPE; FC GAMMA RECEPTOR IIIA; FC RECEPTOR; GRANZYME B; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VPU PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; BINDING ASSAY; CARBOXY TERMINAL SEQUENCE; CASE CONTROL STUDY; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TARGET CELL; BLOOD; CYTOTOXICITY TEST; HIV SURVIVOR; IMMUNOLOGY; SURFACE PLASMON RESONANCE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; SURFACE PLASMON RESONANCE; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 85028344347     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00700-17     Document Type: Article

References (62)

1. Saez-Cirion A, Pancino G. 2013. HIV controllers: a genetically determined or inducible phenotype? Immunol Rev 254:281-294. https://doi.org/10.1111/imr.12076
2. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557. https://doi.org/10.1126/ science.1195271
3. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-571. https://doi.org/10.1086/ 526786
4. Baker BM, Block BL, Rothchild AC, Walker BD. 2009. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 9:55-69. https://doi.org/10.1517/14712590802571928
5. Zaunders J, van Bockel D. 2013. Innate and adaptive immunity in long-term non-progression in HIV disease. Front Immunol 4:95-95. https://doi.org/10.3389/fimmu.2013.00095
6. Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT, Jr, Connors M. 2007. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol 81:2713-2725. https://doi.org/10.1128/JVI.01830-06
7. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897-906. https:// doi.org/10.1097/QAD.0b013e328329f97d
8. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80:4758-4770. https://doi.org/10.1128/JVI.80.10.4758-4770.2006
9. Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, Kramski M, Kent SJ, Stratov I. 2014. Breadth of HIV-1 Env-specific antibodydependent cellular cytotoxicity: relevance to global HIV vaccine design. AIDS 28:1859-1870. https://doi.org/10.1097/QAD.0000000000000310
10. Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, Cooper DA, Stratov I, Navis M, Kent SJ. 2013. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138:116-123. https://doi.org/10.1111/imm.12016
11. Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, Delfraissy JF, Saez-Cirion A, Ferrari G. 2013. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One 8:e74855. https://doi.org/10.1371/journal.pone.0074855
12. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. https://doi.org/10.1038/nature01470
13. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711. https://doi.org/10.1038/31514
14. Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal DN, Overbaugh J. 2015. HIV-specific CD4-induced antibodies mediate broad and potent antibody-dependent cellular cytotoxicity activity and are commonly detected in plasma from HIVinfected humans. EBioMedicine 2:1464-1477. https://doi.org/10.1016/j.ebiom.2015.09.001
15. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. 2011. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412:110-116. https://doi.org/10.1016/j.virol.2010.12.044
16. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, Stratov I. 2011. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A 108:7505-7510. https://doi.org/10.1073/pnas.1016048108
17. Chen J, Tibroni N, Sauter D, Galaski J, Miura T, Alter G, Mueller B, Haller C, Walker BD, Kirchhoff F, Brumme ZL, Ueno T, Fackler OT. 2015. Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma. PLoS One 10:e0120434. https://doi.org/10.1371/journal.pone.0120434
18. Walker BD. 2012. Secrets of the HIV controllers: a rare group of HIVpositive individuals need no medicine to keep the virus in check. Their good fortune could point the way to more powerful treatments-and perhaps a vaccine. Sci Am 307:44-51
19. Shasha D. 2013. Elite controllers and the mechanisms behind spontaneous control of HIV. Harefuah 152:481-485, 498
20. Stratov I, Chung A, Kent SJ. 2008. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 82:5450-5459. https://doi.org/10.1128/JVI.01952-07
21. Lecuroux C, Saez-Cirion A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoel V, Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A. 2014. Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J Virol 88:176-187. https://doi.org/10.1128/JVI.02098-13
22. Kristensen AB, Lay WN, Ana-Sosa-Batiz F, Vanderven HA, Madhavi V, Laurie KL, Carolan L, Wines BD, Hogarth M, Wheatley AK, Kent SJ. 2016. Antibody responses with Fc-mediated functions after trivalent influenza vaccination of HIV-infected subjects. J Virol 90:5724-5734. https://doi.org/10.1128/JVI.00285-16
23. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, Chen W, Wines B, Hogarth PM, Lambe T, Gilbert SC, Parsons MS, Kent SJ. 2016. What lies beneath: antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. EBioMedicine https://doi.org/10.1016/j.ebiom.2016.04.029
24. Wines BD, Vanderven HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. 2016. Dimeric FcgammaR ectodomains as probes of the Fc receptor function of anti-Influenza virus IgG. J Immunol https://doi.org/10.4049/ jimmunol.1502551
25. Klasse PJ. 2016. How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Expert Rev Vaccines 15: 295-311. https://doi.org/10.1586/14760584.2016.1128831
26. Madhavi V, Ana-Sosa-Batiz FE, Jegaskanda S, Center RJ, Winnall WR, Parsons MS, Ananworanich J, Cooper DA, Kelleher AD, Hsu D, Pett S, Stratov I, Kramski M, Kent SJ. 2015. Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy. J Infect Dis 211:529-538. https://doi.org/10.1093/infdis/jiu486
27. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, Komoriya A, Ochsenbauer C, Kappes JC, Roederer M, Huang Y, Weinhold KJ, Tomaras GD, Haynes BF, Montefiori DC, Ferrari G. 2011. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry 79A:603-612. https://doi.org/10.1002/cyto.a.21084
28. Kramski M, Schorcht A, Johnston APR, Lichtfuss GF, Jegaskanda S, De Rose R, Stratov I, Kelleher AD, French MA, Center RJ, Jaworowski A, Kent SJ. 2012. Role of monocytes in mediating HIV-specific antibodydependent cellular cytotoxicity. J Immunol Methods 384:51-61. https:// doi.org/10.1016/j.jim.2012.07.006
29. Poropatich K, Sullivan DJ, Jr. 2011. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol 92:247-268. https://doi.org/10.1099/vir.0.027102-0
30. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270:988-991. https://doi.org/10.1126/science.270.5238.988
31. Santa-Marta M, de Brito PM, Godinho-Santos A, Goncalves J. 2013. Host factors and HIV-1 replication: clinical evidence and potential therapeutic approaches. Front Immunol 4:343. https://doi.org/10.3389/fimmu.2013.00343
32. De Pasquale M, Kourteva Y, Allos T, D'Aquila RT. 2013. Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo. PLoS One 8:e76002. https://doi.org/10.1371/journal.pone.0076002
33. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86:11521-11532. https://doi.org/10.1128/JVI.01023-12
34. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286. https://doi.org/10.1056/NEJMoa1113425
35. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 110: 9019-9024. https://doi.org/10.1073/pnas.1301456110
36. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, Kent SJ, Stratov I. 2011. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 58:127-131. https://doi.org/ 10.1097/QAI.0b013e31822c62b9
37. Banks ND, Kinsey N, Clements J, Hildreth JE. 2002. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 18:1197-1205. https://doi.org/10.1089/08892220260387940
38. Chung AW, Navis M, Isitman G, Centre R, Finlayson R, Bloch M, Gelgor L, Kelleher A, Kent SJ, Stratov I. 2011. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 24:171-175. https:// doi.org/10.1089/vim.2010.0108
39. Forthal DN, Gilbert PB, Landucci G, Phan T. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178:6596-6603. https://doi.org/10.4049/ jimmunol.178.10.6596
40. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Karre K, Kent SJ, Berg L. 2011. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 24:359-368. https://doi.org/10.1089/vim.2011.0025
41. Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey-Kellogg C, Suscovich TJ, Alter G. 2016. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog 12:e1005315. https://doi.org/10.1371/journal.ppat.1005315
42. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O'Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE. 2015. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 7:319ra206. https://doi.org/10.1126/scitranslmed.aad5752
43. Peut V, Kent SJ. 2009. Substantial envelope-specific CD8 T-cell immunity fails to control SIV disease. Virology 384:21-27. https://doi.org/10.1016/ j.virol.2008.11.030
44. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13:46-53. https://doi.org/10.1038/ nm1520
45. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, Dugast AS, Heizen EL, Ercan A, Choi I, Streeck H, Nigrovic PA, Bailey-Kellogg C, Scanlan C, Alter G. 2013. Natural variation in Fc glycosylation of HIVspecific antibodies impacts antiviral activity. J Clin Invest 123:2183-2192. https://doi.org/10.1172/JCI65708
46. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a-TrCP-dependent mechanism. J Virol 83:7931-7947. https://doi.org/10.1128/JVI.00242-09
47. Strebel K. 2014. HIV-1 Vpu-an ion channel in search of a job. Biochim Biophys Acta 1838:1074-1081. https://doi.org/10.1016/j.bbamem.2013.06.029
48. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin AG, Guatelli J, Schwartz O. 2010. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6:e1000955. https://doi.org/ 10.1371/journal.ppat.1000955
49. Hammonds J, Ding L, Chu H, Geller K, Robbins A, Wang JJ, Yi H, Spearman P. 2012. The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release. J Virol 86:2259-2272. https://doi.org/10.1128/JVI.05906-11
50. Arias JF, Evans DT. 2014. Tethering viral restriction to signal transduction. Cell Host Microbe 16:267-269. https://doi.org/10.1016/j.chom.2014.08.013
51. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, Fierer DS, Simon V, Chen BK. 2014. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol 88:6031-6046. https://doi.org/10.1128/JVI.00449-14
52. Pham TN, Lukhele S, Hajjar F, Routy JP, Cohen EA. 2014. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology 11:15. https://doi.org/10.1186/1742-4690-11-15
53. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, Oniangue-Ndza C, Martin M, Li B, Khakoo SI, Carrington M, Allen TM, Altfeld M. 2011. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476:96-100. https://doi.org/10.1038/nature10237
54. Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. 2002. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol 21:671-678. https://doi.org/10.1089/104454902760330219
55. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104. https://doi.org/10.1038/ nature06106
56. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:224-228. https://doi.org/10.1038/nature12744
57. Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. 2015. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 15:793-802. https://doi.org/10.1016/S1473-3099(15)70060-5
58. Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, Young B, Shahar E, Wolff M, Gazzard B, Read T, Hill A, Cooper DA, Emery S. 2014. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383:1474-1482. https:// doi.org/10.1016/S0140-6736(13)62187-X
59. Center RJ, Wheatley AK, Campbell SM, Gaeguta AJ, Peut V, Alcantara S, Siebentritt C, Kent SJ, Purcell DF. 2009. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 27: 6605-6612. https://doi.org/10.1016/j.vaccine.2009.08.016
60. Ma C, Marassi FM, Jones DH, Straus SK, Bour S, Strebel K, Schubert U, Oblatt-Montal M, Montal M, Opella SJ. 2002. Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci 11:546-557. https://doi.org/10.1110/ ps.37302
61. Gong JH, Maki G, Klingemann HG. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652-658
62. Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, Guan Y, Lewis G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J, Finzi A. 2014. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibodydependent cell-mediated cytotoxicity. J Virol 88:2633-2644. https://doi.org/10.1128/JVI.03230-13